目的

探讨新辅助化疗对乳腺癌患者外周血中CD4⁺CD25⁺Foxp3⁺调节性T 细胞(Treg细胞)的影响。

方法

采集68例乳腺癌患者新辅助化疗前1 d和化疗后第10天的外周静脉血,应用流式细胞仪检测外周血中Treg细胞及CD3⁺、CD4⁺及CD8⁺T 细胞占T 淋巴细胞的百分比。定量资料分别采用独立样本或配对样本t检验进行统计分析。

结果

化疗前,乳腺癌患者外周血Treg细胞占T 淋巴细胞的百分比较健康对照组明显增高[(4.77±0.76)%比(0.68%±0.36)%,t=21.176,P=0.000] 。化疗后CD4⁺/CD8⁺较化疗前升高[(1.95±0.72)%比(1.19±0.43)%,t=8.280,P=0.000] ;化疗后Treg细胞较化疗前明显降低[(1.59±0.58)%比(4.77±0.76)%,t=19.041,P=0.000] 。化疗有效组Treg细胞较无效组明显降低,差异有统计学意义(t=8.227,P=0.000)。

结论

新辅助化疗可调控乳腺癌患者机体的肿瘤免疫耐受,改善其免疫功能,从而达到治疗肿瘤的效果。

Objective

To investigate the effect of neoadjuvant chemotherapy on CD4⁺CD25⁺Foxp3⁺ T regulatory(Treg)cells in the peripheral blood of patients with breast cancer.

Methods

A total of 68 samples of peripheral blood of patients with breast cancer were collected on the 1st day before neoadjuvant chemotherapy and the 10th day after neoadjuvant chemotherapy.The proportion of Treg,CD3⁺,CD4⁺and CD8⁺ T cells in peripheral blood in the total amount of T cells was detected by flow cytometry.Independent-sample t test or paired t test was used for the quantitative data analysis.

Results

The percentage of CD4⁺CD25⁺Foxp3⁺regulatory T cells in the peripheral blood of the breast cancer patients before chemotherapy(4.77±0.76)%was significantly higher than that(0.68%±0.36)%in the healthy doners(t=21.176,P=0.000).The proportion of Treg cells in T lymphocytes was significantly decreased from(4.77±0.76)% before neoadjuvant chemotherapy to(1.59±0.58)% after neoadjuvant chemotherapy(t=19.041,P=0.000);but CD4⁺/CD8⁺ was significantly increased from(1.19±0.43)%before neoadjuvant chemotherapy to(1.95±0.72)%after neoadjuvant chemotherapy (t=8.280,P=0.000).The treg cells in the chemotherapy-effective group were significantly decreased compared with the chemotherapy-ineffective group,with a statistical difference between the two groups(t=8.227,P=0.000).

Conclusions

Neoadjuvant chemotherapy can regulate the immune-tolerance of breast cancer patients,and improve their immune function.Neoadjuvant chemotherapy may inhibit tumor through reducing Treg cells in the peripheral blood of patients with breast cancer.